AbbVie Hits a New 52-Week High at $265.97, Clearing Its July Peak
As seen on the 24/7 Wall St. homepage on August 19, 2026.
AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.
Continue ReadingShow less
AbbVie set a new 52-week high of $265.97 on August 19, clearing the July 29 peak and leaving the spring range behind.
Buyers who wait for confirmation are already paying up: the old sellers from that range have been absorbed.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
Momentum carried the stock into the new high without a meaningful pullback in the final leg.
Keep an eye on whether $265.97 holds as support on the first test.
Sources
Mentioned: ABBV